Abstract
Esophageal adenocarcinoma is increasing in the world. The premalignant lesion Barrett's esophagus is also being rapidly recognized. Unfortunately cost effective analyses has shown that the best strategy for prevention is chemoprevention of the premalignant lesion. Of the agents available for chemoprevention aspirin has arguably the best evidence. The efficacy of aspirin cancer prevention is probably now known and rests between 20–30% of the population. The big issues which remain are A. What is the percentage of serious side effects in aspirin takers? B. does concomitant medication abrogate or accentuate the risk benefit ratio? C. What biomarkers or genetic factors predict an optimal risk benefit ratio? The ASPirin Esomeprazole Chemoprevention Trial (ASPECT) is specifically designed to address these issues in patients with Barrett's esophagus.
Citation Information: Cancer Prev Res 2011;4(10 Suppl):ED04-03.